The 23rd Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) will be taking place virtually from May 12-15, 2020. Intellia Therapeutics Inc., a company specializing in genome editing using CRISPR/Cas9, announced that five poster abstracts have been accepted for presentation at this meeting. One specific poster, titled "In Vivo Model Development for Genome-Edited T Cell Therapeutics", demonstrates the use of improved murine models to assess safety, efficacy, and persistence of therapeutic modalities in cell-based therapies. Taconic Biosciences partnered with Intellia Therapeutics to develop two in vivo mouse models, which enabled enhanced monitoring of graft-versus-host disease (GvHD) and human natural killer cytotoxicity.
Read the complete article at: businesstelegraph.co.uk
Read the complete article at: businesstelegraph.co.uk